Baidu
map

Stroke:24小时血管通畅与临床结局和梗死体积的相关性

2017-03-19 MedSci MedSci原创

近期一些随机试验中观察到,与对照组相比,24小时靶血管通畅率在血栓切除术组中更高。近期,一项发表在杂志Stroke上的研究旨在评估治疗组和闭塞位置的24小时血运重建率,因为它们与REVASCAT(前循环的大血管阻塞在症状发作的8小时内呈现的急性中风,比较FR装置与最佳医疗治疗的血管再生的随机对照试验)的临床结果和24小时梗死体积相关。此项研究根据计算机断层扫描/磁共振(94.2%/ 5.8%)血管

近期一些随机试验中观察到,与对照组相比,24小时靶血管通畅率在血栓切除术组中更高。


近期,一项发表在杂志Stroke上的研究旨在评估治疗组和闭塞位置的24小时血运重建率,因为它们与REVASCAT(前循环的大血管阻塞在症状发作的8小时内呈现的急性中风,比较FR装置与最佳医疗治疗的血管再生的随机对照试验)的临床结果和24小时梗死体积相关。

此项研究根据计算机断层扫描/磁共振(94.2%/ 5.8%)血管造影术显示的24小时改良动脉闭塞性病变及计算机断层扫描上24小时梗死体积进行分类,研究独立核心实验室判断的血管状态(血栓切除组中95/103例vs.对照组中94/103)。完全血运重建定义为改良的动脉闭塞病变3级。通过序数逻辑回归分析其对临床结果的影响。

此项研究结果显示:完全血运重建在实验组中发生率为70.5%,在对照组为22.3%(P <0.001)。终末颈内动脉,M1和串联闭塞的完全血运重建率有显着差异(全部P <0.001),但不是M2闭塞。在血栓切除术组中,63名患者(3.1%)中的2名具有改良的2b / 3血栓溶解,并且显示在24小时动脉再闭塞(改良的动脉闭塞性损伤等级0/1)。

在血栓切除术组(调整的优势比,4.5; 95%置信区间,1.9-10.9)和对照组中(调整的优势比,2.7; 95%置信区间,1.0-6.7),均出现完全血运重建与改善的结果相关。两组中,血运重建(改良的动脉闭塞性损伤2/3)均与较小的梗死体积相关。

此项研究结果表明:在24小时出现的完全血运重建是临床结果的有力预测证据;在血栓切除术和对照组中,任何类型的血运重建均可以减少的梗死体积。

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1837221, encodeId=fe1b183e2215f, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Sat Jan 13 04:47:00 CST 2018, time=2018-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1843106, encodeId=aa091843106da, content=<a href='/topic/show?id=3d052296e4e' target=_blank style='color:#2F92EE;'>#临床结局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22967, encryptionId=3d052296e4e, topicName=临床结局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fbd46, createdName=mei531, createdTime=Sat Nov 18 12:47:00 CST 2017, time=2017-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1725257, encodeId=967a1e25257d7, content=<a href='/topic/show?id=e20b101402' target=_blank style='color:#2F92EE;'>#24小时#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1014, encryptionId=e20b101402, topicName=24小时)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=447433741908, createdName=chengjn, createdTime=Fri Jul 07 01:47:00 CST 2017, time=2017-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=181143, encodeId=4acc181143bb, content=学习了……, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/CS7ExJZgQlO85TQ6YlCMZTI3Q0W5AWogEQ1ZcBXdN7icQYJknEZ5ic3rkxRdTicQ6tx5sgX69Jssl8fmLMQ1OFotA/132, createdBy=685b1735507, createdName=Pan Jin, createdTime=Sun Mar 19 13:23:32 CST 2017, time=2017-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=181132, encodeId=848f181132f5, content=签到学习了很多。, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1103841572/A3E53E62691178E2F18D7B999FD22131/100, createdBy=f44d2003846, createdName=Chongyang Zhang, createdTime=Sun Mar 19 12:50:18 CST 2017, time=2017-03-19, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1837221, encodeId=fe1b183e2215f, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Sat Jan 13 04:47:00 CST 2018, time=2018-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1843106, encodeId=aa091843106da, content=<a href='/topic/show?id=3d052296e4e' target=_blank style='color:#2F92EE;'>#临床结局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22967, encryptionId=3d052296e4e, topicName=临床结局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fbd46, createdName=mei531, createdTime=Sat Nov 18 12:47:00 CST 2017, time=2017-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1725257, encodeId=967a1e25257d7, content=<a href='/topic/show?id=e20b101402' target=_blank style='color:#2F92EE;'>#24小时#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1014, encryptionId=e20b101402, topicName=24小时)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=447433741908, createdName=chengjn, createdTime=Fri Jul 07 01:47:00 CST 2017, time=2017-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=181143, encodeId=4acc181143bb, content=学习了……, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/CS7ExJZgQlO85TQ6YlCMZTI3Q0W5AWogEQ1ZcBXdN7icQYJknEZ5ic3rkxRdTicQ6tx5sgX69Jssl8fmLMQ1OFotA/132, createdBy=685b1735507, createdName=Pan Jin, createdTime=Sun Mar 19 13:23:32 CST 2017, time=2017-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=181132, encodeId=848f181132f5, content=签到学习了很多。, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1103841572/A3E53E62691178E2F18D7B999FD22131/100, createdBy=f44d2003846, createdName=Chongyang Zhang, createdTime=Sun Mar 19 12:50:18 CST 2017, time=2017-03-19, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1837221, encodeId=fe1b183e2215f, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Sat Jan 13 04:47:00 CST 2018, time=2018-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1843106, encodeId=aa091843106da, content=<a href='/topic/show?id=3d052296e4e' target=_blank style='color:#2F92EE;'>#临床结局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22967, encryptionId=3d052296e4e, topicName=临床结局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fbd46, createdName=mei531, createdTime=Sat Nov 18 12:47:00 CST 2017, time=2017-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1725257, encodeId=967a1e25257d7, content=<a href='/topic/show?id=e20b101402' target=_blank style='color:#2F92EE;'>#24小时#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1014, encryptionId=e20b101402, topicName=24小时)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=447433741908, createdName=chengjn, createdTime=Fri Jul 07 01:47:00 CST 2017, time=2017-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=181143, encodeId=4acc181143bb, content=学习了……, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/CS7ExJZgQlO85TQ6YlCMZTI3Q0W5AWogEQ1ZcBXdN7icQYJknEZ5ic3rkxRdTicQ6tx5sgX69Jssl8fmLMQ1OFotA/132, createdBy=685b1735507, createdName=Pan Jin, createdTime=Sun Mar 19 13:23:32 CST 2017, time=2017-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=181132, encodeId=848f181132f5, content=签到学习了很多。, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1103841572/A3E53E62691178E2F18D7B999FD22131/100, createdBy=f44d2003846, createdName=Chongyang Zhang, createdTime=Sun Mar 19 12:50:18 CST 2017, time=2017-03-19, status=1, ipAttribution=)]
    2017-07-07 chengjn
  4. [GetPortalCommentsPageByObjectIdResponse(id=1837221, encodeId=fe1b183e2215f, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Sat Jan 13 04:47:00 CST 2018, time=2018-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1843106, encodeId=aa091843106da, content=<a href='/topic/show?id=3d052296e4e' target=_blank style='color:#2F92EE;'>#临床结局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22967, encryptionId=3d052296e4e, topicName=临床结局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fbd46, createdName=mei531, createdTime=Sat Nov 18 12:47:00 CST 2017, time=2017-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1725257, encodeId=967a1e25257d7, content=<a href='/topic/show?id=e20b101402' target=_blank style='color:#2F92EE;'>#24小时#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1014, encryptionId=e20b101402, topicName=24小时)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=447433741908, createdName=chengjn, createdTime=Fri Jul 07 01:47:00 CST 2017, time=2017-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=181143, encodeId=4acc181143bb, content=学习了……, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/CS7ExJZgQlO85TQ6YlCMZTI3Q0W5AWogEQ1ZcBXdN7icQYJknEZ5ic3rkxRdTicQ6tx5sgX69Jssl8fmLMQ1OFotA/132, createdBy=685b1735507, createdName=Pan Jin, createdTime=Sun Mar 19 13:23:32 CST 2017, time=2017-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=181132, encodeId=848f181132f5, content=签到学习了很多。, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1103841572/A3E53E62691178E2F18D7B999FD22131/100, createdBy=f44d2003846, createdName=Chongyang Zhang, createdTime=Sun Mar 19 12:50:18 CST 2017, time=2017-03-19, status=1, ipAttribution=)]
    2017-03-19 Pan Jin

    学习了……

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1837221, encodeId=fe1b183e2215f, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Sat Jan 13 04:47:00 CST 2018, time=2018-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1843106, encodeId=aa091843106da, content=<a href='/topic/show?id=3d052296e4e' target=_blank style='color:#2F92EE;'>#临床结局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22967, encryptionId=3d052296e4e, topicName=临床结局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fbd46, createdName=mei531, createdTime=Sat Nov 18 12:47:00 CST 2017, time=2017-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1725257, encodeId=967a1e25257d7, content=<a href='/topic/show?id=e20b101402' target=_blank style='color:#2F92EE;'>#24小时#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1014, encryptionId=e20b101402, topicName=24小时)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=447433741908, createdName=chengjn, createdTime=Fri Jul 07 01:47:00 CST 2017, time=2017-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=181143, encodeId=4acc181143bb, content=学习了……, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/CS7ExJZgQlO85TQ6YlCMZTI3Q0W5AWogEQ1ZcBXdN7icQYJknEZ5ic3rkxRdTicQ6tx5sgX69Jssl8fmLMQ1OFotA/132, createdBy=685b1735507, createdName=Pan Jin, createdTime=Sun Mar 19 13:23:32 CST 2017, time=2017-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=181132, encodeId=848f181132f5, content=签到学习了很多。, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1103841572/A3E53E62691178E2F18D7B999FD22131/100, createdBy=f44d2003846, createdName=Chongyang Zhang, createdTime=Sun Mar 19 12:50:18 CST 2017, time=2017-03-19, status=1, ipAttribution=)]
    2017-03-19 Chongyang Zhang

    签到学习了很多。

    0

相关资讯

JAMA:间歇性跛行患者——血运重建联合指导性锻炼效果更好

间歇性跛行患者进行指导性锻炼,对其病情的恢复及预后置管重要,指导性锻炼将作为一线治疗方案。血管内血运重建+指导锻炼这一联合治疗方案可能会更加有效。

GW-ICC 2016:吴永健教授谈冠心病血运重建策略如何落地基层医院?

▲ 吴永健教授第二十七届长城国际心血管病会议期间,县域医疗联盟成立后第一次正式会议——县域医疗论坛召开,旨在对基层医师培训冠心病治疗相关技术和理念。一个国家现代化发展水平的高低,往往体现在医疗现代化水平。我国各地区间医疗水平发展不平衡,县级医院数量庞大又承上启下,是我国医疗体系的重要组成部分,因此提高县级医院的诊疗技术水平势在必行。本次会议期间,中国医学科学院阜外医院的吴永健教授详细阐述了冠心

Circulation:雷诺嗪能改善PCI后血运重建患者的心绞痛吗?

经皮冠状动脉介入治疗(PCI)的人群经常伴随心绞痛持续和反复。研究人员假设,雷诺嗪将有效地减少PCI后不完全血运重建(ICR)患者心绞痛和改善生活质量(QOL)。在RIVER-PCI试验中,2604例具有慢性心绞痛病史且PCI术后有ICR的患者吧随机1:1分配接受口服雷诺嗪 vs 安慰剂;QOL分析包括2389例随机参与者。研究人员收集了基线和1,6,和12月的心绞痛和QOL问卷调查。雷诺嗪患者比

2016中国冠状动脉血运重建适宜性标准的建议(试行)发布

药物治疗、经皮冠状动脉介入治疗(PCI)和外科手术治疗是冠心病的主要治疗手段。然而,我国冠心病治疗领域也有一些问题和“不规范”,如何结合我国国情评价我国PCI 的规范化,是否存在过度应用?在哪些方面有所欠缺?患者接受PCI 后,是否真正得到获益?2015 年初受国家卫生计生委的委托,国家心血管病中心发布了《中国冠状动脉血运重建的适宜性标准的建议(试行)》,一是望指导临床医生合理选择PCI 和冠状动

JACC:冠脉疾病合并糖尿病患者应选择怎样的药物治疗和血运重建方案?

目前,通过详细的冠状动脉疾病或左室射血分数(LVEF)血管造影负担分层的2型糖尿病和稳定冠状动脉疾病(CAD)患者的结果数据还比较少。 这项研究确定了最佳药物治疗(OMT)(有或没有经皮冠状动脉介入治疗(PCI)或冠状动脉旁路移植术(CABG)的情况下)对LVEF的长期结果和病变血管数量的影响,包括左前降支近端动脉病变。 来自加拿大的研究人员在3项临床试验中进行了患者水平的汇集

中国PCI指南六大更新:稳定冠心病患者狭窄<90%,干预时需要有缺血证据

近日,《中国经皮冠状动脉介入治疗指南(2016)》发布。

Baidu
map
Baidu
map
Baidu
map